A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination withnivolumab in Patients With Advanced (Unresectable, Re

Project: Research project

Project Details

Description

A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Re
StatusActive
Effective start/end date1/24/236/30/24

Funding

  • DRAGONFLY THERAPEUTICS, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.